Sanctuary Advisors LLC Acquires New Shares in Protalix BioTherapeutics, Inc. (NYSE:PLX)

Sanctuary Advisors LLC bought a new position in shares of Protalix BioTherapeutics, Inc. (NYSE:PLX) during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 37,100 shares of the company’s stock, valued at approximately $38,000. Sanctuary Advisors LLC owned about 0.05% of Protalix BioTherapeutics at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the stock. Cubist Systematic Strategies LLC acquired a new position in Protalix BioTherapeutics in the 2nd quarter valued at $37,000. GSA Capital Partners LLP boosted its holdings in Protalix BioTherapeutics by 8.5% during the third quarter. GSA Capital Partners LLP now owns 435,213 shares of the company’s stock valued at $444,000 after acquiring an additional 33,969 shares during the period. XTX Topco Ltd acquired a new stake in shares of Protalix BioTherapeutics in the third quarter valued at about $36,000. Virtu Financial LLC bought a new position in shares of Protalix BioTherapeutics in the third quarter worth about $44,000. Finally, AQR Capital Management LLC acquired a new position in shares of Protalix BioTherapeutics during the 2nd quarter worth about $67,000. 16.53% of the stock is currently owned by institutional investors.

Protalix BioTherapeutics Price Performance

PLX opened at $1.88 on Wednesday. Protalix BioTherapeutics, Inc. has a fifty-two week low of $0.82 and a fifty-two week high of $1.96. The company has a market capitalization of $138.43 million, a P/E ratio of -14.46 and a beta of 0.74. The firm’s fifty day moving average price is $1.54 and its two-hundred day moving average price is $1.23.

Wall Street Analysts Forecast Growth

Separately, StockNews.com upgraded shares of Protalix BioTherapeutics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, December 12th.

Protalix BioTherapeutics Company Profile

Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.